JC005

(1) To observe the effects of different doses of JC005 on the safety and tolerability of healthy female participants, and to explore the maximum tolerated dose (MTD) of JC005, so as to provide a basis for the dosage in the Phase II clinical trial; (2) To study the pharmacokinetic characteristics of JC005 in healthy women; (3) To preliminarily observe the effects of JC005 on possible efficacy indicators in female participants.